| |
| |
|
| Insider
Information: |
Goodman Corey S |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
12,296,786 |
|
|
Indirect Shares
|
8,829,949 |
|
|
| Direct
Value |
$340,985,692 |
|
|
|
Indirect Value
|
$49,560,123 |
|
|
| Total
Shares |
21,126,735 |
|
|
| Total
Value |
$390,545,815 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -27.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Renovis Inc |
RNVS |
Director |
2008-05-02 |
0 |
2008-05-02 |
0 |
Premium* |
|
|
Pfizer Inc |
PFE |
Senior Vice President |
2009-02-26 |
82,232 |
2009-02-26 |
1,095 |
Premium* |
|
|
Precision Biosciences Inc |
DTIL |
10% Owner |
2019-04-01 |
0 |
2019-04-01 |
4,265,141 |
Premium* |
|
|
Akero Therapeutics, Inc. |
AKRO |
|
2019-06-24 |
0 |
2020-07-06 |
3,033,552 |
Premium* |
|
|
Alx Oncology Holdings Inc |
ALXO |
Executive Chairman, Di... |
|
0 |
2020-07-21 |
515,894 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
|
2020-09-18 |
3,059,123 |
2020-09-18 |
0 |
Premium* |
|
|
Ventyx Biosciences, Inc. |
VTYX |
See Remarks, 10% Owner |
2021-10-25 |
3,997,269 |
2021-10-25 |
1,014,267 |
Premium* |
|
|
Rayzebio, Inc. |
RYZB |
|
2023-09-19 |
5,158,162 |
2023-09-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
82 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RNVS |
Renovis Inc |
President and CEOOfficer |
• • – |
2004-02-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,655,416 |
|
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Director |
– • • |
2020-07-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
461,962 |
|
- |
|
| VTYX |
Ventyx Biosciences, Inc. |
10% Owner |
– – • |
2021-10-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,014,267 |
|
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• – – |
2004-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
3,086 |
370,956 |
|
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2005-09-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,000 |
306,956 |
0 |
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2007-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
395,000 |
403,638 |
0 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2007-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
0 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2008-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
24,144 |
28,253 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2008-05-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(272,823) |
0 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2008-05-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(285,395) |
0 |
0 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2009-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
51,865 |
82,232 |
0 |
- |
|
| DTIL |
Precision Biosciences Inc |
10% Owner |
– – • |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
4,215,141 |
4,265,141 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,704,858 |
3,954,858 |
0 |
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Executive Chairman |
– • • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
7,188,585 |
54,083 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
See Remarks |
• • • |
2020-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,829,123 |
3,059,123 |
0 |
- |
|
| VTYX |
Ventyx Biosciences, Inc. |
See Remarks |
– – • |
2021-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,684,769 |
3,684,769 |
0 |
- |
|
| RYZB |
Rayzebio, Inc. |
|
• • • |
2023-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,158,162 |
5,158,162 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-12 |
4 |
S |
$27.14 |
$163 |
I/I |
(6) |
3,233,671 |
0 |
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2006-12-18 |
4 |
AS |
$3.09 |
$5,725 |
I/I |
(1,852) |
191,956 |
0 |
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2006-11-20 |
4 |
AS |
$3.38 |
$6,262 |
I/I |
(1,852) |
193,808 |
0 |
- |
|
| RNVS |
Renovis Inc |
officerTitle |
• • – |
2006-01-25 |
4 |
AS |
$20.00 |
$11,220 |
I/I |
(561) |
269,895 |
|
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2005-06-03 |
4 |
OE |
$0.81 |
$20,250 |
D/D |
25,000 |
27,926 |
|
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-25 |
4 |
S |
$23.67 |
$37,876 |
I/I |
(1,600) |
3,232,071 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-27 |
4 |
S |
$22.54 |
$40,144 |
I/I |
(1,781) |
3,227,767 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-03-06 |
4 |
S |
$23.79 |
$42,831 |
I/I |
(1,800) |
3,150,019 |
0 |
- |
|
82 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
